Related Experiment Video
Updated: Jul 25, 2025
Organotypic Retinal Explant Cultures from Macaque Monkey
Published on: August 24, 2022
A New Preclinical Model of Retinitis Pigmentosa Due to Pde6g Deficiency
Michelle Carmen Jentzsch1, Stephen H Tsang2,3, Susanne Friederike Koch1
1Department of Pharmacy, Center for Drug Research, Ludwig-Maximilians-Universität München, Munich, Germany.
Insights
A novel mouse model of retinitis pigmentosa (RP) shows rapid photoreceptor degeneration and retinal remodeling, mirroring human disease progression. This study highlights the gamma subunit's role in phosphodiesterase activity and RP development.
Area of Science:
- Ophthalmology
- Genetics
- Molecular Biology
Background:
- Retinitis pigmentosa (RP) is a leading cause of inherited blindness.
- RP involves progressive photoreceptor cell death, impacting downstream retinal cells and vasculature.
- Mutations in the phosphodiesterase 6 (PDE6) gamma subunit cause severe, early-onset RP forms.
Purpose of the Study:
- To analyze the disease progression of retinitis pigmentosa in Pde6g-deficient mice.
- To investigate the role of the PDE6 gamma subunit in RP pathogenesis.
- To establish a novel mouse model for studying RP.
Main Methods:
- Studied Pde6g-/- and Pde6g+/- mice at various postnatal ages.
- Analyzed photoreceptor degeneration and retinal remodeling using immunofluorescence.
- Assessed retinal vasculature, RPE cell structure, and glial cell activation.
Main Results:
- Pde6g-/- mice exhibited rapid rod degeneration by postnatal day 16.
- Observed significant retinal remodeling, including inner neuron changes and RPE abnormalities.
- Degradation of retinal vasculature and early glial cell activation were noted.
Conclusions:
- The Pde6g-/- mouse model accurately replicates human RP progression.
- Results underscore the critical role of the PDE6 gamma subunit in maintaining enzyme activity.
- Provides new insights into the mechanisms of RP caused by Pde6g deficiency.
Purpose:
Retinitis pigmentosa (RP) is the most common cause of inherited blindness, with onset occurring as early as 4 years of age in certain rare but severe forms caused by mutations in the gamma subunit of phosphodiesterase 6 (PDE6). Studies in humans and mice have shown that RP pathology begins with progressive photoreceptor death, which then drives changes in downstream neurons, neighboring retinal pigment epithelium (RPE), and vasculature. Here, we present the first detailed analysis of RP disease progression in Pde6g-deficient mice.
Design:
Experimental study of an RP mouse model.
Subjects:
We studied Pde6g and Pde6g+/- mice at the age of 7, 16, 30, 44, and 56 days with n = 2 to 5 per group and time point.
Methods:
Photoreceptor degeneration and retinal remodeling were analyzed in retinal sections by immunofluorescence. Retinal blood vessel degradation was analyzed in flat-mounted retinas immunolabeled for isolectin GS-IB4. Protein expression was measured by immunoblot. Acellular capillaries were assessed in trypsin-digested and hematoxylin-eosin-stained retinas at postnatal day (P) 44. Retinal pigment epithelium cells were delineated in flat-mounted RPE-choroid-sclera by immunolabeling for the cell-adhesion protein β-catenin.
Main Outcome Measures:
Immunofluorescence and morphometry (quantitative analysis of outer nuclear layer, dendrite area, vessel area, acellular vessels, RPE cell size, number of nuclei per RPE cell, RPE cell eccentricity, and RPE cell solidity).
Results:
This novel RP model exhibits early onset and rapid rod degeneration, with the vast majority gone by P16. This pathology leads to retinal remodeling, including changes of inner retinal neurons, early activation of glia cells, degradation of retinal vasculature, and structural abnormalities of the RPE.
Conclusions:
The pathology in our Pde6g-/- mouse model precisely mirrors human RP progression. The results demonstrate the significant role of the gamma subunit in maintaining phosphodiesterase activity and provide new insights into the disease progression due to Pde6g deficiency.
Financial Disclosures:
Proprietary or commercial disclosure may be found after the references.
